Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)

BACKGROUND: In the phase III TAGS trial, trifluridine/tipiracil showed survival benefit versus placebo in patients with metastatic gastric/gastroesophageal junction cancer and ≥ 2 prior chemotherapies. This post hoc exploratory analysis assessed the impact of prior therapy type on outcomes. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, George, Ben, Taieb, Julien, Sundar, Raghav, Fakih, Marwan G., Makris, Lukas, Benhadji, Karim A., Ghidini, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374776/
https://www.ncbi.nlm.nih.gov/pubmed/37213030
http://dx.doi.org/10.1007/s00432-023-04813-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374776/
https://www.ncbi.nlm.nih.gov/pubmed/37213030
http://dx.doi.org/10.1007/s00432-023-04813-z

Ejemplares similares